Table 1.
MSS, n = 437 (%) | MSI, n = 49 (%) | OR (95% CI) | |
---|---|---|---|
Age (median, 65 y) | |||
<65 | 212 (49) | 17 (35) | Reference |
≥65 | 225 (51) | 32 (65) | 1.77 (0.96–3.290) |
Gender | |||
Female | 212 (49) | 29 (59) | Reference |
Male | 225 (51) | 20 (41) | 0.65 (0.36–1.18) |
Race | |||
Blacks | 204 (47) | 14 (29) | Reference |
Whites | 233 (53) | 35 (71) | 2.19 (1.14–4.18) |
Family history | |||
No | 350 (80) | 35 (71) | Reference |
Yes | 87 (20) | 14 (29) | 1.61 (0.83–3.12) |
Location of tumor | |||
Distal | 165 (45) | 8 (17) | Reference |
Proximal | 205 (55) | 38 (83) | 3.82 (1.74–8.42) |
Stage of cancer at time of diagnosis | |||
Local | 145 (39) | 17 (39) | Reference |
Regional | 210 (59) | 26 (59) | 1.06 (0.55–2.02) |
Distant | 41 (2) | 1 (2) | 0.21 (0.03–1.61) |
Alcohol (category of use) | |||
None | 306 (71) | 27 (56) | Reference |
Lower half | 55 (13) | 8 (17) | 1.65 (0.71–3.82) |
Upper half | 73 (17) | 13 (27) | 2.02 (0.99–4.10) |
Smoking status | |||
Never | 184 (42) | 9 (19) | Reference |
Former | 184 (42) | 26 (54) | 2.89 (1.32–6.33) |
Current | 67 (15) | 13 (27) | 3.97 (1.62–9.70) |
NSAID use during past 5 y | |||
Never | 48 (11) | 10 (21) | Reference |
Occasionally | 177 (40) | 23 (48) | 0.62 (0.28–1.40) |
Frequently | 212 (49) | 15 (31) | 0.34 (0.14–0.80) |
Total calcium intake | |||
Quartile 1 | 113 (26) | 7 (15) | Reference |
Quartile 2 | 109 (25) | 12 (25) | 1.78 (0.68–4.68) |
Quartile 3 | 105 (24) | 16 (33) | 2.46 (0.97–6.22) |
Quartile 4 | 107 (25) | 13 (27) | 1.96 (0.75–5.10) |
Vitamin/supplement use | |||
No/occasional | 264 (61) | 29 (62) | Reference |
Regularly | 166 (39) | 18 (38) | 0.99 (0.53–1.83) |